Adoptive therapies based on CAR/TCR T cells—that is, T cells with an engineered chimeric antigen receptor (CAR) or a T-cell receptor (TCR)—have shown promise for a range of cancers, offering hope to ...
As the next generation of CAR T therapies moves closer to broader commercialization, industry leaders say the future will depend less on choosing between ex vivo and in vivo approaches and more on ...
The US Food and Drug Administration (FDA) outlined its thinking on what sponsors should consider when submitting premarket applications for chimeric antigen receptor (CAR) T cell products, including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results